Grimes & Company’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $479K | Sell |
53,474
-19,233
| -26% | -$172K | 0.01% | 272 |
|
|
2025
Q1 | $545K | Sell |
72,707
-2,568
| -3% | -$19.3K | 0.02% | 232 |
|
|
2024
Q4 | $566K | Hold |
75,275
| – | – | 0.02% | 239 |
|
|
2024
Q3 | $572K | Hold |
75,275
| – | – | 0.02% | 223 |
|
|
2024
Q2 | $465K | Buy |
75,275
+3,836
| +5% | +$23.7K | 0.01% | 227 |
|
|
2024
Q1 | $363K | Sell |
71,439
-916
| -1% | -$4.65K | 0.01% | 251 |
|
|
2023
Q4 | $433K | Sell |
72,355
-1,220
| -2% | -$7.31K | 0.01% | 232 |
|
|
2023
Q3 | $521K | Buy |
73,575
+903
| +1% | +$6.39K | 0.02% | 204 |
|
|
2023
Q2 | $512K | Buy |
72,672
+350
| +0.5% | +$2.46K | 0.02% | 205 |
|
|
2023
Q1 | $603K | Buy |
72,322
+415
| +0.6% | +$3.46K | 0.02% | 184 |
|
|
2022
Q4 | $825K | Sell |
71,907
-40
| -0.1% | -$459 | 0.03% | 171 |
|
|
2022
Q3 | $907K | Buy |
71,947
+948
| +1% | +$12K | 0.05% | 149 |
|
|
2022
Q2 | $751K | Buy |
70,999
+2,238
| +3% | +$23.7K | 0.04% | 162 |
|
|
2022
Q1 | $1.12M | Buy |
68,761
+3,289
| +5% | +$53.5K | 0.06% | 151 |
|
|
2021
Q4 | $907K | Buy |
65,472
+12,801
| +24% | +$177K | 0.04% | 169 |
|
|
2021
Q3 | $757K | Buy |
52,671
+2,066
| +4% | +$29.7K | 0.03% | 176 |
|
|
2021
Q2 | $800K | Sell |
50,605
-1,157
| -2% | -$18.3K | 0.03% | 169 |
|
|
2021
Q1 | $526K | Buy |
51,762
+15,812
| +44% | +$161K | 0.03% | 187 |
|
|
2020
Q4 | $268K | Buy |
35,950
+20,950
| +140% | +$156K | 0.01% | 229 |
|
|
2020
Q3 | $52K | Buy |
+15,000
| New | +$52K | ﹤0.01% | 246 |
|